Innovative long-acting underlying insulin to excellent time (R) was approved in China.

Guide: Provides diabetics with smoother and more effective blood sugar control.
, September 3, 2020 /XINHUA/ -- Sanofi announced that China's State Drug Administration (NMPA) has officially approved the new "insulin glycelin injection" preparation (spec: 1.5 ml: 450 units/pre-filled injection pen) (registered trademark: Toujeo ®, Toujeo ®), hereinafter referred to as Thervendist ® products for adults with type 2 diabetes who require insulin treatment.
The unique slow release mechanism of the ® products makes insulin release slower and more stable after injection under the skin, providing diabetics with smoother and more effective blood sugar control i, more assured of the initial dosing experience i, ii, iii, more flexible injection window i, ii, iii.
The ® product was approved in China based on a phase III clinical study called "EDITIONAP", which included 604 adult type 2 diabetes patients, the study reached the main endpoint, confirming the effectiveness and safety of the ® product in the treatment of type 2 diabetes in adults iv.
compared to existing treatments, the ® products can reduce blood sugar fluctuations, reduce the risk of hypoglycemia, achieve more stable and effective blood sugar standards, and provide a more assured initial tumrapy experience.
An international multicenter randomized controlled study of 929 patients with type 2 diabetes called BRIGHT showed that after 24 weeks of treatment in the optimal ® product group, the glycated hemoglobin (HbA1c®) decreased by 1.64% from the baseline ii;
Based on the overall clinical results, to excellent time® product China registration research leader, Peking University People's Hospital Endocrinology Department Director Professor Ji Linon pointed out that: "To excellent time® product drug action mechanism gives it a good sugar control smoothness, help patients more active and timely dose adjustment optimization;
The approval of the ® products for China's fight against diabetes has added a sophisticated weapon, will help the vast number of patients receiving insulin treatment in China to further improve the rate of sugar compliance.
"Epidemiological survey data show that there are more than 100 million people with type 2 diabetes in China, most of whom are found and diagnosed later, and if insulin supplementation or alternative treatment is required due to disease progression, then basic insulin should be the first choice," said Professor Zhu Dalong, director of the endocrinology department at Gulou Hospital, affiliated with Nanjing University School of Medicine.
Seed time® products, its strong stability and lower low blood sugar risk and other advantages, to meet the existing clinical needs of insulin can not meet, for diabetics to bring new options.
" for many people with diabetes, the onset of insulin can be a challenge, requiring patients to learn not only about the use of injection products, but also about the management of possible hypoglycemia risks.
as an innovative long-acting basis insulin, to excellent time® products with its unique smooth release mechanism, to provide patients with more stable and effective blood sugar control i, lower risk of hypoglycemia, more assured of the initial tmmotic experience ii, more flexible injection time window i, ii, iii, to help patients more peace of mind and convenient starting insulin treatment, and further improve blood sugar control compliance.
"s approval is the sixth ® to land Sanofi in China in 2020.
we are accelerating the introduction of innovative drugs in China at an unprecedented rate.
shows Sanofi's ambitious vision of reversing the spread of chronic diseases by 2030. Dr. Pius S. Hornstein PhD, President of
Sanofi China, said, "With nearly 100 years of experience and heritage in the field of diabetes treatment and excellent time® the successful introduction of Sanofi will bring a smooth and efficient innovative blood glucose management treatment solution to the vast number of diabetic patients in China.
" About the status quo of diabetes in China China is a large country of diabetes, the number of adult diabetes patients reached 129 million v, the highest in the world, at the same time, the awareness rate of diabetes in China is 43%, treatment rate and control rate are less than half, the overall level of control is not optimistic.
there is an urgent clinical need for insulin therapy with a lower risk of hypoglycemia and smoother blood sugar control to improve the situation.
note: partially reduced from the original text.
.